Prostate cancer and supportive care: a systematic review and qualitative synthesis of men's experiences and unmet needs

King, Anna; Evans, Maggie; Moore, Theresa Hm; Paterson, Charlotte; Sharp, Deborah; Persad, Rajendra; Huntley, Alyson

doi:10.1111/ecc.12286

Cited by 157 publications

(179 citation statements)

References 35 publications

(236 reference statements)

Supporting

Mentioning

154

Contrasting

Unclassified

Order By: Relevance

“…The conversations at the Cairn Centre reframed the uncertainties many felt during hospitalisation and treatment. Similarly, in a review of prostate cancer patients' experiences and unmet needs, King et al concluded that one-to-one peer support could alleviate uncertainty and normalise patients' experience of their disease [29]. Peer support seemed to be an important source for quality of life for many patients [30].…”

Section: Benefits For the Patientsmentioning

confidence: 99%

To support and to be supported. A qualitative study of peer support centres in cancer care in Norway

Skirbekk

Korsvold

Finset

2018

Patient Education and Counseling

View full text Add to dashboard Cite

Objective: To explore what peer supporters, patients and their relatives want and gain from peer support in cancer care. Methods:Focus group interviews with peer supporters, and in-depth interviews with peer supporters, patients and relatives (N=38) and observations of daily activities in a Vardesenter ("Cairn Centre").Results: Peer supporters helped cancer patients and relatives with coping in and outside the hospital in several ways: (1) conveying hope and providing ways to cope in situations where despair would often be prevalent, thus protecting against unhealthy stress; (2) being someone who had had the same experiences of disease and treatment, and thus providing a framework for positive social comparisons; and (3) to be an important supplement to family and health care providers. To be working as a peer supporter was also found to be positive and important for the peer supporters themselves. Conclusion:The peer support program represented a valuable supplement to informal support from family and friends and healthcare providers, and gave the peer supporters a new role as "professionally unprofessional". Practice implications:Organised peer support represents a feasible intervention to promote coping for cancer survivors.

show abstract

Section: Benefits For the Patientsmentioning

confidence: 99%

To support and to be supported. A qualitative study of peer support centres in cancer care in Norway

Skirbekk

Korsvold

Finset

2018

Patient Education and Counseling

View full text Add to dashboard Cite

show abstract

“…A dificuldade de adesão da população masculina ao exame de toque vem sendo constatada em diferentes estudos, em diversos contextos (Paiva et al, 2011;Krumwiede & Krumwiede, 2012;Curtis et al, 2013;Oliveira et al, 2014;King et al, 2015;Martins & Modena, 2016b). O momento da realização do exame de toque, também denominado pelos entrevistados como dedada, foi marcado por sentimentos de medo, vergonha e constrangimento e foi vivenciado como um procedimento muito invasivo e desconfortável.…”

Section: A Realização Dos Exames Preventivos Do Câncer Na Próstataunclassified

“…Além do incômodo físico, o procedimento desencadeia desconforto psicológico, no qual ao medo da descoberta de uma enfermidade grave se associa o receio de uma ereção durante o procedimento, gerando, assim, o temor de ser percebido pelo médico e pela equipe de saúde como um homossexual. Assim, a realização do exame de toque retal produz nos homens a sensação de redução de sua virilidade (Curtis et al, 2013;Martins et al, 2014;Modena et al, 2014;King et al, 2015;Martins & Modena, 2016b).…”

Section: A Realização Dos Exames Preventivos Do Câncer Na Próstataunclassified

Representações Sociais De Corpo Após O Adoecimento Por Câncer Na Próstata

Martins¹,

Nascimento²

2017

Psicol Estud

View full text Add to dashboard Cite

RESUMO.O estudo tem como objetivo identificar e analisar as Representações Sociais de corpo para homens após o adoecimento por câncer na próstata. Foram realizadas entrevistas narrativas com oito homens com idade entre 50 e 70 anos, diagnosticados com câncer na p róstata e que realizaram tratamento oncológico há pelo menos um ano. As entrevistas foram gravadas, transcritas e analisadas por meio da Abordagem Fenomenológica Interpretativa. Os resultados apontam que antes do adoecimento, os participantes representavam seus corpos como fortes, resistentes e saudáveis, tendo no modelo de masculinidade hegemônica um importante ponto de ancoragem para estas representações. A ausência de sintomas que provocassem desconfortos corporais contribuiu para a percepção de corpo sa udável. A busca por serviços de saúde somente ocorreu após a manifestação e agravamentos dos primeiros sintomas, que limitaram suas ações diárias e alteraram o seu cotidiano. O adoecimento por câncer na próstata e as propostas de tratamento oncológico, em especial, a prostatectomia, foram destacados pelos participantes como uma experiência marcante e produtora de grande desconforto físico e psicológico. Após o adoecimento, os homens passaram a representar os seus corpos como frágeis, doentes e debilitados. Os entrevistados chamam a atenção para o impacto das transformações corporais, especialmente aquelas relacionadas às disfunções sexuais e urológicas, nos modos de pensar, sentir e agir, em relação à própria masculinidade. Nesse sentido, as limitações impos tas pelo adoecimento e tratamento oncológico se contrapõem ao modelo de masculinidade hegemônica, favorecendo o sentimento de ser menos homem do que antes do adoecimento. Palavras-chave:Câncer na próstata; masculinidade; representação social. SOCIAL REPRESENTATIONS OF THE BODY AFTER THE ILLNESS BY PROSTATE CANCERABSTRACT. This study aims to identify and analyze the social representations of body for men after the illness from prostate cancer. Narrative interviews were conducted with 08 men with age s ranging from 50 and 70 years, diagnosed with this disease and who had undergone oncological treatment, for at least one year. The interviews were recorded, transcribed and analyzed using the Interpretative Phenomenological Approach. The results show that before the illness, the participants represented their bodies as strong, resistant and healthy taking in the hegemonic masculinity model an important anchorage point for these representations. The absence of symptoms that cause bodily discomforts contribu ted to the feeling of healthy body. The search for health services only occurred after the manifestation of the first symptoms and its exacerbations, which limited their daily actions and change their daily lives. Participants mentioned the illness by prostate cancer and oncological treatment proposals, in particular the prostatectomy, as a remarkable experience that producer of great physical and psychological discomfort. After the illness, the men began to represent their bodies as fragile, sick a...

show abstract

“…Prostate cancer (PCa) is the most common malignancy in men (1). In patients affected by advanced PCa, defined as hormonesensitive disease since the tumor still requires androgen for growth, androgen deprivation therapy (ADT), including luteinizing hormone-releasing hormone (LHRH) agonists, antagonists and anti-androgens, represents the first-line treatment.…”

Section: Abstract 223 Ra Prolongs Overall Survival In Symptomatic Pamentioning

confidence: 99%

Radium-223: Insight and Perspectives in Bone-metastatic Castration-resistant Prostate Cancer

Buroni

Persico

Pasi

et al. 2016

View full text Add to dashboard Cite

Abstract. 223 Prostate cancer (PCa) is the most common malignancy in men (1). In patients affected by advanced PCa, defined as hormonesensitive disease since the tumor still requires androgen for growth, androgen deprivation therapy (ADT), including luteinizing hormone-releasing hormone (LHRH) agonists, antagonists and anti-androgens, represents the first-line treatment. Unfortunately some cancer cells develop resistance to ADT, indicating the progression of the disease to metastatic castration-resistant prostate cancer (mCRPCa). Such resistance to castration occurs in most patients (2) and, despite the approval of new therapeutic agents, mCRPCa remains a lethal disease (3). Nowadays the new therapeutic landscape for patients affected by mCRPCa aims to extend overall survival (OS) and includes cytotoxic, new-generation anti-androgens, immunotherapeutics and radiopharmaceuticals (4, 5).Bones are the preferred site of metastasis. Almost 90% of men who die from PCa have bone-metastatic disease (6), with a 5-year OS rate of 20%. Due to the fragility of bone with metastases, with the related risk of pain, fractures, spinal cord compression and hematological consequences, several drugs have been developed to treat the osseous involvement of this disease. In previous years, the optimal treatment aimed to relieve pain and reduce skeletal morbidity.Besides systemic therapies, bone-targeted agents that focus their activity on bone, such as bisphosphonates, monoclonal antibody and radiopharmaceuticals, have become available. The bisphosphonate zoledronic acid, the antibody to receptor activator of nuclear factor kappa-B ligand (RANKL) denosumab and radiopharmaceuticals [such as 89 Sr and 153 Sm-ethylene diamine tetramethylene phosphonate ( 153 Sm-EDTMP)], were approved for delaying skeletal-related events (SREs) and for the palliation of bone pain from mCRPCa. Radionuclide TherapyRadionuclide therapy is known to deliver ionizing radiation to tumor sites, thereby killing cancer cells (7). Bone-targeted radiopharmaceuticals localize their radiation to sites of high bone remodeling. 5719

show abstract

Prostate cancer and supportive care: a systematic review and qualitative synthesis of men's experiences and unmet needs

Cited by 157 publications

References 35 publications

To support and to be supported. A qualitative study of peer support centres in cancer care in Norway

To support and to be supported. A qualitative study of peer support centres in cancer care in Norway

Representações Sociais De Corpo Após O Adoecimento Por Câncer Na Próstata

Radium-223: Insight and Perspectives in Bone-metastatic Castration-resistant Prostate Cancer

Contact Info

Product

Resources

About